Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

LAMIVUDINE, NEVIRAPINE, AND STAVUDINE

LAMIVUDINE, NEVIRAPINE, AND STAVUDINE

Standard Dose
150MG;200MG;30MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: None (Tentative Approval)
Summary

Approval overview LAMIVUDINE, NEVIRAPINE, AND STAVUDINE is listed in Drugs@FDA under application 022537 (NDA).

Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient LAMIVUDINE, NEVIRAPINE, AND STAVUDINE Form and strength TABLET; ORAL - 150MG;200MG;30MG Sponsor MACLEODS PHARMA Submission history Latest submission status date: 2010-08-30 00:00:00.

Structured Monograph

Clinical summary

Approval overview LAMIVUDINE, NEVIRAPINE, AND STAVUDINE is listed in Drugs@FDA under application 022537 (NDA). Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient LAMIVUDINE, NEVIRAPINE, AND STAVUDINE Form and strength TABLET; ORAL - 150MG;200MG;30MG Sponsor MACLEODS PHARMA Submission history Latest submission status date: 2010-08-30 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: None (Tentative Approval)
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.